Home >> Research Area >>Tyrosine Kinase/Adaptors>>VEGFR>> Dovitinib Dilactic acid

Dovitinib Dilactic acid

CAS# 852433-84-2

Dovitinib Dilactic acid

Catalog No. BCC3771----Order now to get a substantial discount!

Product Name & Size Price Stock
Dovitinib Dilactic acid: 5mg $69 In Stock
Dovitinib Dilactic acid: 10mg Please Inquire In Stock
Dovitinib Dilactic acid: 20mg Please Inquire Please Inquire
Dovitinib Dilactic acid: 50mg Please Inquire Please Inquire
Dovitinib Dilactic acid: 100mg Please Inquire Please Inquire
Dovitinib Dilactic acid: 200mg Please Inquire Please Inquire
Dovitinib Dilactic acid: 500mg Please Inquire Please Inquire
Dovitinib Dilactic acid: 1000mg Please Inquire Please Inquire
Related Products

Quality Control of Dovitinib Dilactic acid

Number of papers citing our products

Chemical structure

Dovitinib Dilactic acid

3D structure

Chemical Properties of Dovitinib Dilactic acid

Cas No. 852433-84-2 SDF Download SDF
PubChem ID 135985126 Appearance Powder
Formula C27H33FN6O7 M.Wt 572.59
Type of Compound N/A Storage Desiccate at -20°C
Solubility Soluble in DMSO > 10 mM
Chemical Name 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-quinolin-2-one;2-hydroxypropanoic acid
SMILES CC(C(=O)O)O.CC(C(=O)O)O.CN1CCN(CC1)C2=CC3=C(C=C2)N=C(N3)C4=C(C5=C(C=CC=C5F)NC4=O)N
Standard InChIKey XXLPVQZYQCGXOV-UHFFFAOYSA-N
Standard InChI InChI=1S/C21H21FN6O.2C3H6O3/c1-27-7-9-28(10-8-27)12-5-6-14-16(11-12)25-20(24-14)18-19(23)17-13(22)3-2-4-15(17)26-21(18)29;2*1-2(4)3(5)6/h2-6,11H,7-10H2,1H3,(H,24,25)(H3,23,26,29);2*2,4H,1H3,(H,5,6)
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months.
Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it.
About Packaging 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial.
2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial.
3. Try to avoid loss or contamination during the experiment.
Shipping Condition Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request.

Dovitinib Dilactic acid Dilution Calculator

Concentration (start)
x
Volume (start)
=
Concentration (final)
x
Volume (final)
 
 
 
C1
V1
C2
V2

calculate

Dovitinib Dilactic acid Molarity Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
g/mol

calculate

Preparing Stock Solutions of Dovitinib Dilactic acid

1 mg 5 mg 10 mg 20 mg 25 mg
1 mM 1.7465 mL 8.7323 mL 17.4645 mL 34.929 mL 43.6613 mL
5 mM 0.3493 mL 1.7465 mL 3.4929 mL 6.9858 mL 8.7323 mL
10 mM 0.1746 mL 0.8732 mL 1.7465 mL 3.4929 mL 4.3661 mL
50 mM 0.0349 mL 0.1746 mL 0.3493 mL 0.6986 mL 0.8732 mL
100 mM 0.0175 mL 0.0873 mL 0.1746 mL 0.3493 mL 0.4366 mL
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations.

Organizitions Citing Our Products recently

 
 
 

Calcutta University

University of Minnesota

University of Maryland School of Medicine

University of Illinois at Chicago

The Ohio State University

University of Zurich

Harvard University

Colorado State University

Auburn University

Yale University

Worcester Polytechnic Institute

Washington State University

Stanford University

University of Leipzig

Universidade da Beira Interior

The Institute of Cancer Research

Heidelberg University

University of Amsterdam

University of Auckland
TsingHua University
TsingHua University
The University of Michigan
The University of Michigan
Miami University
Miami University
DRURY University
DRURY University
Jilin University
Jilin University
Fudan University
Fudan University
Wuhan University
Wuhan University
Sun Yat-sen University
Sun Yat-sen University
Universite de Paris
Universite de Paris
Deemed University
Deemed University
Auckland University
Auckland University
The University of Tokyo
The University of Tokyo
Korea University
Korea University

Background on Dovitinib Dilactic acid

Dovitinib Dilactic acid is a potent, non-specific growth factor receptor kinase inhibitor with effects against FLT-3, c-KIT, VEGFR, PDGFRß and CSF-1R, respectively.

Featured Products
New Products
 

References on Dovitinib Dilactic acid

Dovitinib dilactic acid reduces tumor growth and tumor-induced bone changes in an experimental breast cancer bone growth model.[Pubmed:30956945]

J Bone Oncol. 2019 Mar 19;16:100232.

Advanced breast cancer has a high incidence of bone metastases. In bone, breast cancer cells induce osteolytic or mixed bone lesions by inducing an imbalance in bone formation and resorption. Activated fibroblast growth factor receptors (FGFRs) are important in regulation of tumor growth and bone remodeling. In this study we used FGFR1 and FGFR2 gene amplifications containing human MFM223 breast cancer cells in an experimental xenograft model of breast cancer bone growth using intratibial inoculation technique. This model mimics bone metastases in breast cancer patients. The effects of an FGFR inhibitor, Dovitinib Dilactic acid (TKI258) on tumor growth and tumor-induced bone changes were evaluated. Cancer-induced bone lesions were smaller in dovitinib-treated mice as evaluated by X-ray imaging. Peripheral quantitative computed tomography imaging showed higher total and cortical bone mineral content and cortical bone mineral density in dovitinib-treated mice, suggesting better preserved bone mass. CatWalk gait analysis indicated that dovitinib-treated mice experienced less cancer-induced bone pain in the tumor-bearing leg. A trend towards decreased tumor growth and metabolic activity was observed in dovitinib-treated mice quantified by positron emission tomography imaging with 2-[(18)F]fluoro-2-deoxy-D-glucose at the endpoint. We conclude that dovitinib treatment decreased tumor burden, cancer-induced changes in bone, and bone pain. The results suggest that targeting FGFRs could be beneficial in breast cancer patients with bone metastases.

Description

Dovitinib Dilactic acid (TKI258 Dilactic acid) is the Dilactic acid of Dovitinib, which is a multitargeted RTK inhibitor, mostly for class III (FLT3/c-Kit) with IC50 of 1 nM/2 nM, also potent to class IV (FGFR1/3) and class V (VEGFR1-4) RTKs with IC50 of 8-13 nM, less potent to InsR, EGFR, c-Met, EphA2, Tie2, IGFR1 and HER2. Phase 4.

Keywords:

Dovitinib Dilactic acid,852433-84-2,Natural Products,VEGFR, buy Dovitinib Dilactic acid , Dovitinib Dilactic acid supplier , purchase Dovitinib Dilactic acid , Dovitinib Dilactic acid cost , Dovitinib Dilactic acid manufacturer , order Dovitinib Dilactic acid , high purity Dovitinib Dilactic acid

Online Inquiry for:

      Fill out the information below

      • Size:Qty: - +

      * Required Fields

                                      Result: